Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for Apellis Pharmaceuticals (APLS) over the last 6 years, with Dec 2024 value amounting to $1.8 million.

  • Apellis Pharmaceuticals' Depreciation & Amortization (CF) fell 25.82% to $339,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 8.11%. This contributed to the annual value of $1.8 million for FY2024, which is 0.73% up from last year.
  • According to the latest figures from FY2024, Apellis Pharmaceuticals' Depreciation & Amortization (CF) is $1.8 million, which was up 0.73% from $1.8 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $1.8 million during FY2024, and its lowest value of $637,000 during FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $1.7 million, with a median of $1.8 million in 2023.
  • Data for Apellis Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY surged of 165.42% (in 2020) over the last 5 years.
  • Apellis Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $637,000 in 2020, then skyrocketed by 116.48% to $1.4 million in 2021, then grew by 12.55% to $1.6 million in 2022, then increased by 14.95% to $1.8 million in 2023, then climbed by 0.73% to $1.8 million in 2024.